REDUCE-RISKinCD-PIBD -TRIAL
Research type
Research Study
Full title
Risk Stratified randomised controlled trial in paediatric Crohn's Disease: Methotrexate versus azathioprine or adalimumab for maintaining remission in patients at low or at high risk for aggressive disease course, respectively - a treatment strategy
IRAS ID
234353
Contact name
Richard Russell
Contact email
Sponsor organisation
PIBD net
Eudract number
2016-000522-18
Clinicaltrials.gov Identifier
Duration of Study in the UK
2 years, 10 months, 1 days
Research summary
Crohn's disease is a chronic recurrent inflammatory disorder, which can cause tissue and bowel damage leading to major disability if not treated adequately. Chronic and uncontrolled intestinal inflammation results in poor outcome in patients with Crohn's disease resulting in reduced quality of life, more surgery, hospital admissions etc. The main aim of this study is to determine if a more aggressive treatment at disease onset increases the likelihood of deep remission thereby improving long term outcomes.
REC name
North West - Liverpool Central Research Ethics Committee
REC reference
18/NW/0037
Date of REC Opinion
28 Mar 2018
REC opinion
Further Information Favourable Opinion